
Grown Rogue International Inc.
93
Recent developments include acquisition activities, management changes, and ongoing expansion efforts amid regulatory processes.
- Grown Rogue acquired the remaining 30% stake in its Illinois subsidiary for $1.5 million in September 2025, consolidating ownership [N15].
- The company appointed a new CFO in April 2026 as part of its expansion plans [N16].
Grown Rogue International Inc. operates in the cannabis sector through various subsidiaries and is engaged in cultivation, distribution, and retail activities. The company is pursuing growth via acquisitions, including a pending deal for PharmaCann of New York, LLC, which requires regulatory approval and involves financial exposure. Its Illinois operations depend on the license of SEA Craft, LLC, with a 49% acquisition pending approval. The company has reported recent financial results showing revenue generation alongside net losses and maintains liquidity to cover short-term obligations. Management changes include the appointment of a new CFO amid expansion plans.
Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice. Grown Rogue International Inc. is a cannabis company with active operations and expansion efforts, including acquisitions pending regulatory approval. The company reported quarterly revenue of $11.0 million and a net loss of $8.9 million as of September 30, 2026, with liquidity ratios indicating coverage of short-term liabilities. Risks include regulatory approvals for acquisitions and operational dependencies on licenses.
The company’s acquisition strategy and expansion into new markets through regulatory-approved licenses could enhance its operational scale and revenue base. Its liquidity position and management changes aimed at supporting growth initiatives may strengthen execution capabilities. The established subsidiaries and operational licenses provide a platform for potential market share gains in regulated cannabis markets.
Regulatory approvals for key acquisitions remain uncertain, posing risks to planned expansions and financial exposure from deposits and lease liabilities. The company’s net losses and ongoing cash burn highlight profitability challenges. Dependence on licenses held by third parties and regulatory scrutiny could impair operations. Market competition and regulatory changes in the cannabis sector add to execution risks.
Grown Rogue's moat is primarily based on its licensed operations in regulated cannabis markets, including Illinois and New York, and its strategic acquisitions that expand its footprint. Regulatory approvals and licenses are critical barriers to entry, and the company's established presence and operational infrastructure provide competitive positioning. However, the moat is subject to regulatory risk and market competition inherent in the cannabis industry.
• Regulatory Approval Risks: Pending acquisitions require regulatory approvals which may be denied or conditioned, potentially resulting in loss of investments and operational disruptions.
• Financial Exposure from Acquisitions: The company has advanced funds and deposits toward acquisitions that may be lost if deals do not close, and may remain liable under leases related to these acquisitions.
• Operational Dependency on Licenses: Operations in Illinois depend on licenses held by SEA Craft, with acquisition pending approval; loss or restriction of these licenses could materially impact business.
• Profitability and Cash Flow Risks: The company reported net losses and negative earnings per share, indicating ongoing challenges in achieving profitability and managing cash flow.
Business trends: The company is actively pursuing acquisitions and expansion in regulated cannabis markets, with revenue generation alongside net losses.
Execution milestones: Completion of pending acquisitions, regulatory approvals, and integration of new management are key execution points.
Key risks: Regulatory approval uncertainties, financial exposure from acquisitions, operational dependency on licenses, and ongoing profitability challenges.
Very high visibility
Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).
- Grown Rogue International Inc. operates in the cannabis industry with multiple subsidiaries including Grown Rogue New York, LLC and SEA Craft, LLC.
- The company is engaged in acquisitions and expansions, including a pending acquisition of PharmaCann of New York, LLC (PCNY), which requires regulatory approval and involves financial exposure and operational integration risks.
- Grown Rogue acquired the remaining 30% stake in its Illinois subsidiary for $1.5 million in 2025.
- The company appointed a new CFO amid expansion plans as of April 2026.
- As of September 30, 2026, the company reported quarterly revenue of approximately $11.0 million and a net loss of about $8.9 million, with basic and diluted EPS of -$0.04 per share.
- The company had cash and cash equivalents of approximately $10.1 million as of December 31, 2025, and current assets of about $30.7 million with current liabilities of $14.4 million as of September 30, 2026, resulting in a current ratio of 2.14 and a cash ratio of 0.7, indicating liquidity coverage of short-term obligations.
- The company’s Illinois operations depend on SEA Craft’s license, with a 49% acquisition pending regulatory approval, posing potential risks if approval is denied or conditions are imposed.
- The pending acquisition of PCNY exposes the company to financial and accounting risks, including potential loss of deposits and liabilities under leases if the acquisition is not completed.
- The company provides support services and financing to PCNY and subleases facilities while remaining liable under master leases.
- Recent news coverage includes business developments related to the company’s acquisitions and management changes, but broader market news is mostly unrelated to the company’s core operations.
Generated 2026-11-14
- S1 | 2026-05-01 | 10-K/A
- S2 | 2026-11-13 | 10-Q
- N1 | 2026-11-14 | www.nasdaq.com | Soybeans Post Friday Gains Following Export Announcements | https://www.nasdaq.com/articles/soybeans-post-friday-gains-following-export-announcements
- N2 | 2026-11-14 | www.nasdaq.com | Soybeans Popping Higher on Friday Following Export Announcements | https://www.nasdaq.com/articles/soybeans-popping-higher-friday-following-export-announcements
- N3 | 2026-11-14 | www.nasdaq.com | Tariffs Pushed Prices Up. Why Retail and Industrial Investors Shouldn't Expect a Quick Reversal | https://www.nasdaq.com/articles/tariffs-pushed-prices-why-retail-and-industrial-investors-shouldnt-expect-quick-reversal
- N4 | 2026-11-14 | www.nasdaq.com | Arrive AI: 3 Key Takeaways for Long-Term Investors | https://www.nasdaq.com/articles/arrive-ai-3-key-takeaways-long-term-investors
- N5 | 2026-11-14 | www.nasdaq.com | Novo Nordisk Secures EU Approval For FREHEMGO In Haemophilia A | https://www.nasdaq.com/articles/novo-nordisk-secures-eu-approval-frehemgo-haemophilia
- N6 | 2026-11-14 | www.nasdaq.com | COSCIENS Biopharma Inc. Q3 Loss Widens | https://www.nasdaq.com/articles/cosciens-biopharma-inc-q3-loss-widens
- N7 | 2026-11-14 | www.nasdaq.com | Alphamin Resources Corp. Profit Climbs In Q3 | https://www.nasdaq.com/articles/alphamin-resources-corp-profit-climbs-q3
- N8 | 2026-11-14 | www.nasdaq.com | Bragg Gaming Group Inc. Q3 Loss Rises | https://www.nasdaq.com/articles/bragg-gaming-group-inc-q3-loss-rises
This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Generated by Valye SEC Pipeline Engine
.gif)


